Published in Br J Cancer on July 20, 2001
Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumours. Br J Cancer (2004) 1.11
Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer (2007) 1.05
p73 Interacts with human immunodeficiency virus type 1 Tat in astrocytic cells and prevents its acetylation on lysine 28. Mol Cell Biol (2005) 0.96
Expression and clinical significance of TAp73alpha, p53, PCNA and apoptosis in hepatocellular carcinoma. World J Gastroenterol (2005) 0.78
Homozygous deletion of TNFRSF4, TP73, PPAP2B and DPYD at 1p and PDCD5 at 19q identified by multiplex ligation-dependent probe amplification (MLPA) analysis in pediatric anaplastic glioma with questionable oligodendroglial component. Mol Cytogenet (2014) 0.75
p53 mutations in human cancers. Science (1991) 31.96
A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet (1997) 12.94
p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell (1998) 11.54
Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell (1997) 7.27
p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature (2000) 5.83
p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature (1997) 5.42
Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol (1994) 3.66
The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci (2000) 2.55
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature (2000) 2.10
Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene (1999) 1.91
Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. Cancer Res (1999) 1.69
Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res (1998) 1.55
Molecular pathways in the formation of gliomas. Glia (1995) 1.43
p53 mutations in nonastrocytic human brain tumors. Cancer Res (1991) 1.42
Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res (1998) 1.39
Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer (1995) 1.37
Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res (1995) 1.33
p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene (1999) 1.22
NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene (1999) 1.21
Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differ (1999) 1.20
Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene (1991) 1.19
Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol (1999) 1.16
Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene (2001) 1.15
Structure, function and regulation of p63 and p73. Cell Death Differ (1999) 1.12
Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood (1999) 1.08
Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet (1995) 1.05
1p36: every subband a suppressor? Eur J Cancer (1995) 1.05
Mutational analysis of p73 and p53 in human cancer cell lines. Oncogene (1999) 1.01
Mutation analysis of P73 and TP53 in Merkel cell carcinoma. Br J Cancer (2000) 1.00
Infrequent somatic mutations of the p73 gene in various human cancers. Eur J Surg Oncol (1999) 1.00
Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. Genomics (1998) 0.98
A device for processing large acrylamide gels. Biotechniques (1994) 0.97
High-resolution analysis of chromosome arm 1p alterations in meningioma. Cancer Genet Cytogenet (2000) 0.94
DNA damage enables p73. Nature (1999) 0.94
Alterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype. Int J Cancer (1999) 0.87
Search for mutations of the hRAD54 gene in sporadic meningiomas with deletion at 1p32. Mol Carcinog (1999) 0.87
Loss of heterozygosity for distal markers on 22q in human gliomas. Int J Cancer (1992) 0.84
hRAD54 gene and 1p high-resolution deletion-mapping analyses in oligodendrogliomas. Cancer Genet Cytogenet (2000) 0.84
Genetic alternations of p73 are infrequent but may occur in early stage hepatocellular carcinoma. Anticancer Res (2000) 0.79
Differential expression and allelotyping of the p73 gene in neuroblastoma. Int J Oncol (2000) 0.78
The p73 gene is not mutated in oligodendrogliomas which frequently have a deleted region at chromosome 1p36.3. Anticancer Res (2000) 0.77
Allelic losses and genetic instabilities of PTEN and p73 in non-Hodgkin lymphomas. Leukemia (2000) 0.76
Evaluating the message: the relationship between compliance rate and the subject of a practice guideline. Med Care (1994) 5.05
Evidence of self-report bias in assessing adherence to guidelines. Int J Qual Health Care (1999) 4.96
Controlling health expenditures--the Canadian reality. N Engl J Med (1989) 4.36
Laparoscopy for abdominal emergencies: evidence-based guidelines of the European Association for Endoscopic Surgery. Surg Endosc (2005) 4.12
Aging and health care utilization: new evidence on old fallacies. Soc Sci Med (1987) 4.02
Determinants of the increasing cesarean birth rate. Ontario data 1979 to 1982. N Engl J Med (1984) 3.16
Trends in use of medical services by the elderly in British Columbia. CMAJ (1989) 2.88
Paying physicians in Canada: minding our Ps and Qs. Health Aff (Millwood) (1989) 2.84
Do physician-payment mechanisms affect hospital utilization? A study of Health Service Organizations in Ontario. CMAJ (1996) 2.72
Do health service organizations and community health centres have higher disease prevention and health promotion levels than fee-for-service practices? CMAJ (1990) 2.07
Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet (1994) 1.99
Monitoring the diffusion of a technology: coronary artery bypass surgery in Ontario. Am J Public Health (1988) 1.86
Protection by lactate of cerebral function during hypoglycaemia. Lancet (1994) 1.86
Recent trends in cesarean section rates in Ontario. CMAJ (1989) 1.85
Re-minding our Ps and Qs: medical cost controls in Canada. Health Aff (Millwood) (1996) 1.82
Supply projections as planning: a critical review of forecasting net physician requirements in Canada. Soc Sci Med (1985) 1.68
Camino intracranial pressure monitor: prospective study of accuracy and complications. J Neurol Neurosurg Psychiatry (2000) 1.62
Flat on your back or back to your flat? Sources of increased hospital services utilization among the elderly in British Columbia. Soc Sci Med (1990) 1.53
Bridges between health care research evidence and clinical practice. J Am Med Inform Assoc (1996) 1.48
Thalamic cavernous malformation. Case report. J Neurosurg (1990) 1.43
[Cutaneous epithelial necrosis in coma. Study of 2 cases]. Rev Clin Esp (1991) 1.39
Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer (1995) 1.37
Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care (1997) 1.27
Regional differences in cerebral blood flow and glucose utilization in diabetic man: the effect of insulin. J Cereb Blood Flow Metab (1998) 1.26
NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene (1999) 1.21
Regionalization of coronary artery bypass surgery. Effects on access. Med Care (1989) 1.21
The long good-bye: the great transformation of the British Columbia hospital system. Health Serv Res (1989) 1.20
Quality assurance and effectiveness in health care: an overview. Qual Assur Health Care (1990) 1.18
MLPA vs multiprobe FISH: comparison of two methods for the screening of subtelomeric rearrangements in 50 patients with idiopathic mental retardation. Clin Genet (2006) 1.16
Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer (1994) 1.15
Estimates of the potential impact of nurse practitioners on future requirements for physicians in office-based general practice. Can J Public Health (1985) 1.14
Comparative study of three diagnostic approaches (FISH, STRs and MLPA) in 30 patients with 22q11.2 deletion syndrome. Clin Genet (2005) 1.13
Research and evidence-based decision making. Aust N Z J Public Health (1997) 1.09
Explaining variations in cesarean section rates: patients, facilities or policies? Can Med Assoc J (1985) 1.08
Cutaneous metastases from prostatic carcinoma. J Surg Oncol (1996) 1.06
Placing patients in the queue for coronary revascularization: evidence for practice variations from an expert panel process. Am J Public Health (1990) 1.05
p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer (1998) 1.05
Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother (1999) 1.05
Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet (1995) 1.05
Delay in onset of awareness of acute hypoglycemia and of restoration of cognitive performance during recovery. Diabetes Care (2000) 1.04
Is radical hepatic surgery safe? Am J Surg (1998) 1.04
Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer (1994) 1.04
Inhibition of Fas signaling prevents hepatic injury and improves organ blood flow during sepsis. Surgery (2001) 1.02
Does the community want devolved authority? Results of deliberative polling in Ontario. CMAJ (1995) 0.98
Aberrant methylation of multiple genes in neuroblastic tumours. relationship with MYCN amplification and allelic status at 1p. Eur J Cancer (2003) 0.97
Molecular and cytogenetic analysis of chromosome 9 deletions in 75 malignant gliomas. Genes Chromosomes Cancer (1994) 0.97
Cytogenetic recombinants from a female carrying a paracentric inversion of the short arm of chromosome number 5. Hum Genet (1983) 0.96
Frontal osteomas: standardising therapeutic indications. J Laryngol Otol (2011) 0.95
Chromosomal composition of a series of 22 human low-grade gliomas. Cancer Genet Cytogenet (1987) 0.95
Home is where the governing is: social capital and regional health governance. Health Place (1999) 0.95
High-resolution analysis of chromosome arm 1p alterations in meningioma. Cancer Genet Cytogenet (2000) 0.94
Lack of preservation of higher brain function during hypoglycaemia in patients with intensively-treated IDDM. Diabetologia (1995) 0.94
Chromosomal patterns in human malignant astrocytomas. Cancer Genet Cytogenet (1987) 0.93
Quantitation and stability of piperacillin and tazobactam in plasma and ultrafiltrate from patients undergoing continuous venovenous hemofiltration by HPLC. Biomed Chromatogr (2005) 0.92
Clear-cell porocarcinoma: another cutaneous marker of diabetes mellitus. Am J Dermatopathol (1997) 0.92
Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations. Neuropathol Appl Neurobiol (2005) 0.90
Familial progressive supranuclear palsy. Description of a pedigree and review of the literature. Brain (1995) 0.90
Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther (1996) 0.90
CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br J Cancer (2003) 0.90
Clonal chromosome aberrations in neurinomas. Genes Chromosomes Cancer (1993) 0.89